Category Archives: Biotechnology

Jeanmarie Guenot Displays Scientific Expertise in the Development of Drugs to Combat Blood Cancer

 

Jeanmarie Guenot is a longtime professional in the biotechnology and pharmaceutical industries, with over 20 years of experience. Her working experience includes working in public and private firms, R & D, corporate and commercial development sector, venture capital, business development, and project, alliance management, and company building and rebuilding. Presently, she is the president and chief executive officer of Amphivena Therapeutics Incorporation. http://amphivena.com/amphivena_leaders/jeanmarie-guenot-ph-d/

 

Amphivena Therapeutics has its headquarters in San Francisco, California. The corporation develops progressive autoimmune therapy techniques to combat hematologic health conditions. In July 2013, the company received 14 million dollars from a funding sponsored by MPM Capital. Later that year, Amphivena signed an agreement with Janssen Biotech Incorporation to allow Janssen the right to acquire Amphivena in the case of an IND approval. In 2015, Amphivena and Janssen announced its achievement in selecting a medical candidate to help in further development of treatment of hematologic malignancies and the hidden tumor antigen. Amphivena then received an undisclosed payment, following an agreement with Johnson & Johnson Innovation.

 

According to her website, Jeanmarie Guenot graduated from the University of California with a PhD from the University of Pennsylvania and with an MBA from the Wharton school. She then trained for quantum mechanical and semi-empirical methodologies for molecular dynamics, and X-Ray, protein built prediction, drug design, and NMR refinement. Jeanmarie began her career at the Atlas Venture and was responsible for managing the venture capital investments and building the life science firms. She then moved on to specialize in science by working for Preclinical R & D as a chief scientist. Jeanmarie developed and discovered drugs to treat metabolic illnesses, autoimmune complications, inflammation, and oncology.

 

Dr. Guenot’s notable career achievements include building and operating the SKS Ocular that managed glaucoma therapeutics, ocular inflammation, and macular degeneration. She served Hoffmann-La Roche as a business advisor in their Basel and Shanghai offices before moving on to work for PDL BioPharma as the vice president of the firm and corporate development division.

Jeanmarie Guenot aims to eliminate blood cancers by developing innovative therapies that adapt to a patient’s immune system. The treatment is set to destroy tumor cells and their causative agents. The treatment will treat blood cancer by rebalancing the cellular environment needed for healthy blood creation, functioning, and circulation.

Seattle Genetics CEO, Clay Siegall Discusses Enterprising Expansion Plan

Seattle Genetics, a cancer research, and drug company, has announced its plans to expand its drug portfolio and at the same time employ over 120 people in its US and Switzerland offices. The announcement came amidst recent visit by vice president Joe Bidden who visited the region to see the progress of cancer research.

With the company already having over 800 employees in their books, the larger percentage of the new hires will serve in operations as opposed to research. The US office can hold 350 more people and therefore Seattle Genetics will add 100 new employees in the US while 20 will be employed in the Switzerland office. After hiring about 500 people in the last five years, an average of 100 people annually, there is no doubt the company has been growing rapidly. This year Seattle Genetics is on track to maintain that trend by hiring more than 120 people.

The company puts Seattle on the map and underlines it as a center for cancer research. The master plan by Dr. Seigall includes rolling out 12 new cancer therapy drugs.

According to Dr. Siegall, the results of the drug will largely affect the company. Adcetris, a ‘frontline’ treatment for lymphoma has generated $226 million in revenues in the US and Canada alone. The predicted revenues in 2016 will range between $255 million and $275 million after partnering with a pharmaceutical company that will sell the drug in other parts of the world.

About Clay Siegall

For his education, Dr. Siegall attended the University of Maryland where he earned a B.S degree in Zoology. He is also a Ph.D. holder in Genetics after he achieved his doctorate from Washington University. Dr. Clay Siegall Co-Founded Seattle Genetics Inc. in 1998. He currently serves in three positions within the company. He is the president and CEO as well as the Chairman of the board of directors of the company.

Besides co-establishing Seattle Genetics, Dr. Siegall had experienced a rich history of working in medical having worked for almost a decade for two medical research centers. He is currently a board member of several private biotechnology companies including Ultragenyx Pharmaceuticals, Mirna Therapeutics, and Alder Biopharmaceuticals.